Notice of Preliminary Results and Presentation
Avacta Group PLC has announced that it will release its unaudited preliminary results for the year ended December 31, 2025, on May 19, 2026. The company's Chief Executive Officer and Chief Financial Officer will host a live investor presentation on the same day at 14:00 BST, which will be accessible to existing and potential shareholders. Questions can be submitted in advance by May 18, 2026, or during the presentation. The results and presentation will also be available on the company's website.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| LONDON AND PHILADELPHIA - May 13, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre | CISION®, a tumor-activated oncology delivery platform, confirms it will announce its unaudited preliminary results for the year ended December 31, 2025 ("FY25"), on May 19, 2026. |
Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial Officer, will deliver a live presentation via Investor Meet Company at 14:00 BST on May 19, 2026.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 BST on May 18, 2026, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via: https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.
The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.
About AVA6103 (FAP-Exd)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.